- Report
- January 2026
- 188 Pages
Global
From €3458EUR$3,939USD£2,992GBP
- Report
- January 2026
- 187 Pages
Global
From €3458EUR$3,939USD£2,992GBP
- Report
- August 2025
- 192 Pages
Global
From €3458EUR$3,939USD£2,992GBP
- Report
- September 2025
- 250 Pages
Global
From €3942EUR$4,490USD£3,410GBP
- Report
- February 2026
- 50 Pages
Global
From €2326EUR$2,650USD£2,013GBP
Nevirapine is an antiretroviral drug used to treat HIV/AIDS. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by blocking the action of the enzyme reverse transcriptase, which is essential for the replication of the virus. Nevirapine is used in combination with other antiretroviral drugs to treat HIV infection. It is also used to prevent mother-to-child transmission of HIV during childbirth.
Nevirapine is a widely used drug in the treatment of infectious diseases, particularly HIV/AIDS. It is an important part of combination antiretroviral therapy (cART) and is recommended by the World Health Organization (WHO) for the treatment of HIV infection. Nevirapine is also used to prevent mother-to-child transmission of HIV during childbirth.
Nevirapine is available in both generic and branded forms. It is manufactured by several pharmaceutical companies, including Cipla, Mylan, and Teva Pharmaceuticals. It is also available in combination with other antiretroviral drugs, such as efavirenz and lamivudine.
In the Nevirapine market, companies such as Cipla, Mylan, and Teva Pharmaceuticals are major players. Other companies include Aurobindo Pharma, Hetero Drugs, and Sun Pharmaceuticals. Show Less Read more